A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Lung Cancer
DRUG: BMS-986507|DRUG: Osimertinib|DRUG: Pembrolizumab
Number of participants with adverse events (AEs), Up to 3 years|Number of participants with serious adverse events (SAEs), Up to 3 years|Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) critera, Up to 3 years|Number of participants with AEs leading to discontinuation, Up to 3 years|Number of participants with AEs leading to death, Up to 3 years|Number of DLTs that occur during the DLT evaluation period, Up to 3 weeks
Maximum observed serum concentration (Cmax), Up to 3 years|Time of maximum observed concentration (Tmax), Up to 3 years|Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)), Up to 3 years|Area under the serum concentration-time curve within a dosing interval (AUC(TAU)), Up to 3 years|Objective response rate (ORR), Up to 3 years|Duration of response (DOR), Up to 3 years
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.